Early Increase of Circulating Transitional B Cells and Autoantibodies to Joint‐Related Proteins in Patients With Metastatic Melanoma Developing Checkpoint Inhibitor–Induced Inflammatory Arthritis
Authors' conclusion
Development of ICI-IA is accompanied by an increase in transitional B cells and by production of autoantibodies to joint-related proteins.
Study context
- Population
- Patients receiving immune checkpoint inhibitors (ICIs) to treat metastatic melanoma
- Participants
- 7 vs 15
- Exposure
- ICI-induced inflammatory arthritis (IA) vs no immune-related adverse events after ICIs for metastatic melanoma
- ICI-induced IA (ICI-IA)n = 7
- non-IRAEn = 15reference
- Outcome
- Proportion of CD19+ B cells
Methodological detailsconsecutive recruitment, flow cytometry
- Consecutive recruitment
- Flow cytometry
Main finding
As reported in the abstract
P = 0.03
Observational data: associations, not effects.
Further findings
Absolute number of transitional B cells
P < 0.01
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Higher transitional B cell levels and development of ICI-IA | 2.25 (1.03–4.9) | P = 0.04 | |
| 0.20.5125Odds ratio (log scale) |
| Outcome | ICI-IA | non-IRAE | P value |
|---|---|---|---|
| Proportion of transitional CD19+CD10+CD24high CD38high B cellsMedian | 8.1% (IQR 4.9–12.1%) | 3.6% (IQR 1.9–4.9%) | P < 0.01 |
| Autoantibodies to type II collagen epitopes | 43% | 0 events | P = 0.02 |
- Autoantibodies to type II collagen epitopes: detected in up to 43% of ICI-IA patients
Transitional B cells over time in ICI-IA
- Increased before onset of overt ICI-IA and decreased between active and quiescent stages (P = 0.02)
Original publication
Early Increase of Circulating Transitional B Cells and Autoantibodies to Joint‐Related Proteins in Patients With Metastatic Melanoma Developing Checkpoint Inhibitor–Induced Inflammatory Arthritis. Arthritis Rheumatol. Published 14 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →